10.05.2022 Evotec SE  DE0005664809

DGAP-Adhoc: Evotec and Bristol Myers Squibb extend and expand strategic partnership


 

DGAP-Ad-hoc: Evotec SE / Key word(s): Miscellaneous
Evotec and Bristol Myers Squibb extend and expand strategic partnership

10-May-2022 / 16:29 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces today that the Company has extended and expanded its partnership with Bristol Myers Squibb (NYSE:BMY) in targeted protein degradation, originally signed in 2018.

Aim of the eight-year extension is to develop a broad pipeline of molecular glue degraders which are small, drug-like compounds. Bristol Myers Squibb is a leader in this field in particular based on its unique library CELMoD®.

Under the terms of the agreement, Evotec’s proprietary EVOpanOmics and EVOpanHunter platforms as well as AI/ML-based drug discovery and development platforms will be leveraged.

Evotec receives an upfront payment of $ 200 m and expects to obtain further performance-based, near-term and programme-based milestone payments, resulting in a deal potential of $ 5 bn with additional tiered royalties on product sales.

– End of ad hoc release –

Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560 81-242, [email protected]


10-May-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 1348655

 
End of Announcement DGAP News Service

1348655  10-May-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1348655&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 164,51 257,63 375,41 446,44 500,92 618,03 715,00
EBITDA1,2 36,23 57,22 95,46 123,14 51,77 109,29 115,00
EBITDA-Marge3 22,02 22,21 25,43 27,58 10,33 17,68 16,08
EBIT1,4 31,34 37,50 77,46 62,59 48,52 41,00 0,00
EBIT-Marge5 19,05 14,56 20,63 14,02 9,69 6,63 0,00
Jahresüberschuss1 26,84 24,00 84,06 37,23 6,25 215,51 0,00
Netto-Marge6 16,32 9,32 22,39 8,34 1,25 34,87 0,00
Cashflow1,7 67,36 10,83 156,24 42,22 44,72 122,24 0,00
Ergebnis je Aktie8 0,20 0,16 0,46 0,25 0,04 1,30 -0,05
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

INVESTOR-INFORMATIONEN
©boersengefluester.de
Evotec
WKN Kurs in € Einschätzung Börsenwert in Mio. €
566480 17,955 Halten 3.177,18
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
64,13 35,60 1,80 72,69
KBV KCV KUV EV/EBITDA
2,31 25,99 5,14 24,21
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,00 0,00 0,00 22.06.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
11.05.2022 11.08.2022 09.11.2022 26.04.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-23,59% -32,98% -57,75% -55,80%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Evotec SE  ISIN: DE0005664809 können Sie bei EQS abrufen


Biotechnologie , 566480 , EVT , XETR:EVT